截至2026年1月26日 13:16，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，华兰生物领涨 5.00%，英科医疗上涨2.54%，华润三九上涨1.16%；南微医学领跌。医疗创新ETF(516820)下跌最新报 价0.37元。 生物医药概念午后快速拉升，消息面上，1月下旬，印度西孟加拉邦突发尼帕病毒疫情，已造成多名医 护人员感染，泰国、尼泊尔紧急升级防控。 数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 从资金净流入方面来看，医疗创新ETF近6天获得连续资金净流入，最高单日获得4053.70万元净流入， 合计"吸金"8499.86万元，日均净流入达1416.64万元。（数据来源：Wind） 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金 ...

而如何为其提供专业化的投后赋能，更决定了项目是否能带来可持续性的回报。目前高特佳已搭建了聚焦"深度行业研究+丰富生态资源+成熟资本运作"为 特色的专业投后赋能平台，辐射战略咨询、产业对接、人才引进、品牌公关、融资服务等多个模块，助力生态圈企业价值提升。 展望未来，高特佳投资将继续坚守医疗健康单一赛道，深化专业壁垒。无论时代如何演进，生老病死的自然规律不会因技术飞跃而改变，健康始终是人类最 本质、最永恒的追求。在这一不可动摇的需求基石上，生物医药产业展现出穿越周期的强大韧性。从精准靶向的创新疗法，到普惠可及的预防保障，生物医 药产业所彰显出不可替代的战略价值，证明该赛道存在永续的投资机遇。高特佳投资将持续以金融资本的力量，发现并培育具有全球竞争力的创新企业，推 动中国生物医药产业的高质量发展，为投资人创造长期价值，为健康中国建设贡献专业力量。 高特佳投资是中国私募股权投资领域为数不多、长期坚持聚焦于单一赛道的专业投资机构。2001年高特佳投资在深圳成立，率先在业内提出"主题行业投 资"的投资模式，专注医疗健康产业投资。历经25年深耕，构建起跨越周期的产业认知体系与独特的价值投资框架。 高特佳投资资产管理规模超2 ...

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [29]. Core Insights - The MSCI China Healthcare Index has increased by 9.2% since the beginning of 2026, outperforming the MSCI China Index, which rose by 5.6% [1]. - The pharmaceutical industry has seen significant growth, driven by strong institutional investor interest and the ongoing trend of innovative drugs going global [1]. - The report emphasizes the importance of clinical progress and data validation for pipelines that have already gone overseas, suggesting that this trend will continue in the long term [1]. Summary by Sections Industry Overview - The report highlights a robust trend in the outbound licensing of innovative drugs, with multiple business development (BD) transactions occurring at the start of 2026, reflecting a high level of activity in the sector [4]. - Key transactions include significant upfront and milestone payments for various drugs, indicating strong market interest and potential for future growth [4]. Company Ratings and Valuations - The report provides detailed valuations for several companies, including: - **Sangfor Technologies (1530 HK)**: Market cap of $7,598.4 million, target price of $37.58, with a 54% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $963.3 million, target price of $44.95, with a 46% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,551.0 million, target price of $88.00, with a 28% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,951.4 million, target price of $9.40, with a 42% upside potential [2]. Market Trends - The report notes that the competition in the PD-(L)1/VEGF space is intensifying, with several companies advancing their clinical trials and aiming for first-line indications [4]. - The report suggests that the efficiency and breadth of clinical trials, as well as the richness of combination therapies, will be critical factors in determining success in this competitive landscape [4].

Summary of Expert Call on China's IVD Market Industry Overview - **Industry**: In-vitro diagnostics (IVD) market in China - **Expert**: Mr. Fang, an IVD distributor with over 15 years of experience Key Points Market Size and Growth Trends - **Q425 Market Performance**: - **Chemiluminescent immunoassay (CLIA)**: -12% YoY in test volume and -16% YoY in revenue, but showed QoQ recovery as panel test unbundling policies ended [2][8] - **Clinical Chemistry**: -5% YoY in both volume and revenue, with volume-based procurement (VBP) largely completed [2][8] - **Haematology**: +6% YoY in both volume and revenue, driven by high influenza A incidence [2][8] - **Haemostasis**: +5% YoY in both volume and revenue [2][8] - **Molecular Testing**: +9% YoY in revenue, also supported by influenza A [2][9] - **Point of Care Tests (POCT)**: -11% YoY in both volume and revenue, due to a shift to CLIA and suspension of non-compliant prescriptions [2][9] Competitive Landscape - **Channel Inventory**: - CLIA: Global brands have 3 months of sales in inventory, down 2 weeks from Q325; domestic brands have 6-10 weeks [3][14] - Haematology: Mindray and Sysmex have 14 weeks and 5 months of sales in inventory, respectively, expected to reduce in 2026 [3][17] - **Import Substitution**: - Significant gains for domestic companies like Mindray in CLIA and haemostasis, while overseas companies like Roche and Siemens lost market share [3][12][28] 2026 Market Outlook - **Growth Projections**: - **CLIA**: Expected to shrink by 2% YoY despite a 2-3% increase in test volume [4][19] - **Clinical Chemistry**: Anticipated growth of 2% YoY [4][20] - **Haematology**: Expected growth of 5% YoY, assuming no national policy headwinds [4][21] - **Haemostasis**: Expected growth of 6% YoY [4][22] - **Molecular Testing**: Expected growth of 7% YoY [4][23] - **POCT**: Expected decline of 6% YoY [4][24] Policy Impacts - **Testing Fee Unification**: Seen as a major swing factor for market growth in 2026, with potential price cuts of 30-40% for reagents not covered by VBPs [4][35][37] - **VBP Implementation**: Five provinces have initiated VBP programs, with full implementation expected by Q126 [29] Risks and Considerations - **Market Risks**: - Potential for larger-than-expected price reductions and smaller market share gains from VBP programs [40] - Weaker demand from equipment renewal programs and geopolitical issues affecting supply chains [40] Additional Insights - The expert noted that the impact of the Chinese New Year on sales growth was about 5-6% YoY due to later occurrence in 2026 compared to 2025 [7] - The expert expressed a more positive outlook for CLIA in 2026 compared to previous estimates, reflecting recent QoQ recovery [4][24] This summary encapsulates the key insights from the expert call regarding the current state and future outlook of China's IVD market, highlighting growth trends, competitive dynamics, and the impact of policy changes.

Group 1 - The core viewpoint of the news highlights the performance of the medical innovation sector, with the China Securities Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Hualan Biological at a 0.90% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past six days, with a peak single-day net inflow of 40.54 million yuan, totaling 84.99 million yuan and an average daily net inflow of 14.17 million yuan [1] - Central China Television announced that Galaxy General Robotics will be the designated humanoid robot for the 2026 Spring Festival Gala, marking a significant milestone for the company established in May 2023, which focuses on a wide range of applications including retail, industrial, medical, and cultural tourism [1] Group 2 - The China Securities Medical and Medical Device Innovation Index consists of 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the medical and medical device sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, collectively accounting for 63.75% of the index [2] Group 3 - The current medical device sector is at a turning point, with performance recovery expected in 2026, driven by new technologies such as AI in healthcare, brain-machine interfaces, and surgical robots, leading to a continuous revaluation of innovative products with global competitiveness [1]

Group 1 - The core index, the CSI Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index, has shown a slight increase of 0.03% as of January 23, 2026, with notable stock performances including Jiejia Weichuang up by 20.00% and Xunwei Communication up by 15.43% [1] - The Greater Bay Area ETF (512970) has increased by 0.26%, with a latest price of 1.56 yuan, and has accumulated a rise of 0.64% over the past two weeks [1] - The trading liquidity of the Greater Bay Area ETF was 3.75% during the session, with a total transaction volume of 3.33 million yuan, and an average daily transaction of 990,200 yuan over the past month [1] Group 2 - The tracking error of the Greater Bay Area ETF over the past six months is reported at 0.026%, indicating a close alignment with the underlying index [2] - The CSI Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index includes a maximum of 50 Hong Kong stocks, 300 companies from the Shanghai-Hong Kong-Shenzhen market, and 100 mainland market securities, all selected based on their relevance to the Greater Bay Area development theme [2] - As of December 31, 2025, the top ten weighted stocks in the index account for 46.96% of the total index weight, with major companies including China Ping An, Luxshare Precision, and BYD [2] Group 3 - The top ten stocks by weight in the index have shown varied performance, with China Ping An down by 1.39% and Luxshare Precision down by 1.61%, while Mindray Medical has increased by 1.04% [4] - The weight distribution of the top ten stocks includes China Ping An at 8.31%, Luxshare Precision at 6.59%, and BYD at 6.05%, among others [4]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector, specifically highlighting companies like Yuyuan Pharmaceutical and CanSino Biologics for their promising developments in mRNA vaccines [1]. Core Insights - The mRNA vaccine sector is experiencing a breakthrough, with mRNA technology leading the shift towards efficient and personalized immunotherapy. This technology offers three core competitive advantages: rapid production capabilities, enhanced safety profiles, and flexibility in antigen design, which supports personalized treatment approaches [1][4]. - The report identifies a favorable ranking of sub-industries, with innovative drugs, research services, and CXO services being prioritized for investment. High-yield sectors include traditional Chinese medicine and pharmacies [10][11]. - Specific companies are recommended for investment based on various therapeutic angles, including PD1 PLUS, ADC, and small nucleic acids, with notable mentions such as Innovent Biologics, CanSino Biologics, and Yuyuan Pharmaceutical [10][12][13]. Summary by Sections Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.10%. The Hang Seng Biotechnology Index has also seen a 12.40% increase [4][9]. - Sub-sectors such as pharmaceutical commerce (+4.26%) and raw materials (+2.41%) have performed well, while bioproducts and chemical pharmaceuticals have faced declines [4][9]. Clinical Developments - Corcept Therapeutics has reported positive results from its Phase III trial for relacorilant, indicating survival benefits for patients with platinum-resistant ovarian cancer. Meanwhile, Maiwei Biologics has initiated its first patient dosing in the U.S. for its CDH17-ADC innovative drug [1][4]. Investment Recommendations - The report suggests a diversified investment approach across various therapeutic areas, including: - PD1 PLUS: Focus on companies like 3SBio and Innovent Biologics - ADC: Companies such as InnoCare Pharma and Kintor Pharmaceutical - Small nucleic acids: Recommendations include Frontier Biotechnologies and Yuyuan Pharmaceutical - Traditional Chinese medicine: Companies like Zhaoke Pharmaceutical and Fangsheng Pharmaceutical are highlighted [10][12][13]. Fund Holdings - The report notes a decrease in the proportion of public fund holdings in the pharmaceutical sector, with a total holding of 6.67% as of Q4 2025, down 1.46 percentage points from the previous quarter [17][18]. Company Performance - Specific companies have been highlighted for their market performance, with notable increases in stock prices for companies like *ST Changyao (+70.37%) and Hualan Biological (+32.21%) [9]. This comprehensive analysis provides insights into the current state and future potential of the pharmaceutical and biotechnology industry, emphasizing the importance of mRNA technology and strategic investment in key companies.

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, specifically highlighting companies such as Yuyuan Pharmaceutical and CanSino Biologics for potential investment opportunities [1]. Core Insights - The mRNA vaccine sector is experiencing significant advancements, with mRNA technology leading the shift towards efficient and personalized immunotherapy. This technology offers three main competitive advantages: rapid production capabilities, enhanced safety profiles, and flexibility in antigen design, which supports tailored treatments for cancer patients [1][4]. - The report identifies promising sub-sectors within the industry, ranking them as follows: innovative drugs, research services, CXO, traditional Chinese medicine, medical devices, and pharmacies. It suggests a focus on high-growth areas such as innovative drugs, particularly in small nucleic acid therapies, and high-dividend sectors like traditional Chinese medicine and pharmacies [10][11]. Summary by Sections Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.10%. The Hang Seng Biotechnology Index has also seen a year-to-date rise of 12.40% [4][9]. - Notable performers in the market include *ST Changyao (+70.37%) and Hualan Biological (+32.21%) for the week, while the worst performers include Kain Technology (-13.83%) and Aidi Pharmaceutical (-13.70%) [9]. Clinical Developments - Corcept Therapeutics has reported positive results from its Phase III trial for relacorilant, which shows survival benefits for patients with platinum-resistant ovarian cancer. Additionally, Maiwei Biologics has initiated its first patient dosing in the U.S. for its CDH17-ADC innovative drug targeting advanced colorectal and gastrointestinal tumors [4]. Investment Recommendations - Specific companies to watch include: - From the PD1 PLUS perspective: 3SBio, Kanyin Biologics, Innovent Biologics, and Zai Lab [11]. - From the ADC perspective: InnoCare Pharma, Kelun-Biotech, and Baillie Gifford [11]. - From the small nucleic acid perspective: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [11]. - From the self-immune perspective: Kangnuo Pharmaceutical, Yifang Biologics, and Yipinhong [11]. - From the innovative drug leaders: BeiGene and HengRui Medicine [11]. - From the CXO and upstream research services: WuXi AppTec, Haoyuan Pharmaceutical, and Aopumai [11]. - From the medical device sector: United Imaging Healthcare and Yuyue Medical [11].

Market Overview - The pharmaceutical sector is experiencing a structural bull market in 2025, with the CITIC Pharmaceutical Index rising nearly 30% in the first three quarters, driven by the global recognition of the value of innovative drugs and devices [2][3] - The industry is expected to enter a critical phase of innovation realization and global expansion in 2026, shifting investment logic from expectation-driven to closely tracking clinical data, commercialization progress, and international achievements [2][3] Valuation Insights - The pharmaceutical sector's valuation remains at historical lows, with significant investment opportunities still available. As of December 31, 2025, various sub-sectors are trading at relatively low valuations, such as biopharmaceuticals at 35.16X and medical devices at 33.07X [7][9] - The medical services, chemical raw materials, and chemical preparations sectors have shown impressive growth, with increases of 29.22%, 22.03%, and 20.44% respectively [7] Revenue and Profit Trends - From January to November 2025, China's pharmaceutical manufacturing industry reported total revenue of 220.65 billion yuan, a year-on-year decline of 2.51%, while total profit decreased by 1.79% [9] - The performance of the biopharmaceutical, medical services, and pharmaceutical distribution sectors has improved, with biopharmaceuticals benefiting from rapid drug volume growth post-collection [9] Fund Management and Investment Opportunities - As of the end of Q3 2025, public funds' holdings in the pharmaceutical sector were at 11.22%, below the ten-year average of 8.15%, indicating potential for excess returns as the sector approaches a performance inflection point [11] - The low allocation of public funds and the sector's historical low valuations present significant opportunities for investment in high-potential sub-sectors and individual stocks [11] Innovation and Policy Support - The Chinese biopharmaceutical industry is entering a new phase of high-quality development, with significant improvements in innovation capabilities among the top 100 pharmaceutical companies [14][21] - The government has implemented comprehensive policies to support the development of innovative drugs and medical devices, transitioning from single-item support to a full-chain, regional, and financial support system [15][28] Global Market Position - China has become the second-largest market for innovative drug launches globally, contributing approximately 30% of the world's innovative pipelines as of Q3 2025 [50][66] - The country is increasingly recognized for its efficiency and cost-effectiveness in drug development, with a significant number of clinical trials initiated in China, particularly in oncology [53][66] Licensing and Commercialization Trends - The number of license-out transactions for Chinese innovative drugs has surged, with 103 deals recorded in the first three quarters of 2025, totaling $92.03 billion, marking a 77% increase year-on-year [43][63] - The successful inclusion of innovative drugs in the new commercial insurance directory is expected to enhance their commercialization prospects [30] Future Growth Areas - Next-generation therapies, including ADCs, bispecific antibodies, and cell and gene therapies, are becoming focal points for research and investment, with China leading in these areas [76][87] - The oncology drug market is projected to reach $441 billion, with new therapies expected to account for about 20% of treatment expenditures by 2029 [82]

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry but emphasizes a positive outlook on various segments within the industry, particularly innovative drugs and medical devices [9][10]. Core Insights - The pharmaceutical industry is transitioning from a quantity-driven logic to a quality-driven logic, focusing on differentiated products and internationalization by 2025 [9]. - There is a notable shift in funding from active to passive medical funds, indicating a low allocation status in the pharmaceutical sector, which is expected to change as passive funds become a significant part of the investment landscape [16][17]. - The report outlines a structured approach to ETF investment in the pharmaceutical sector, emphasizing a dynamic combination of broad-based and targeted strategies to balance returns and risks [27]. Summary by Sections Market Review - The CITIC Pharmaceutical Index decreased by 0.38%, outperforming the CSI 300 Index by 0.24 percentage points, ranking 25th among 30 sectors [6]. - The top-performing stocks included *ST Changyao, Hualan Biological Engineering, and Kangzhong Medical, while the worst performers were Kaiyin Technology and Aidi Pharmaceutical [6]. Innovative Drugs - The report highlights a positive outlook for domestic innovative drugs, suggesting a focus on companies that can deliver profits, such as BeiGene, Innovent Biologics, and others [9]. Medical Devices - The medical device sector is expected to see a recovery in bidding volumes for imaging equipment by 2025, with a focus on companies like Mindray and United Imaging [9]. - The home medical device market is also anticipated to grow due to supportive policies and accelerated international expansion [9]. Innovation Chain (CXO + Life Science Services) - The report indicates a potential recovery in overseas investment and financing, with domestic financing expected to stabilize, marking the beginning of a new wave of innovation [9]. Pharmaceutical Industry - The report suggests that the specialty API sector may see cost improvements, leading to a new growth cycle, with companies like Tonghua Dongbao and Huahai Pharmaceutical highlighted for their potential [9]. Traditional Chinese Medicine - The report discusses the expected growth in the basic drug market and the impact of state-owned enterprise reforms on companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical [11]. Pharmacy Sector - The report expresses optimism about the pharmacy sector due to the acceleration of prescription outflow and the optimization of competitive dynamics, recommending companies like YaoXing and YiFeng Pharmacy [11]. Medical Services - The report notes that anti-corruption measures and centralized procurement are improving the market environment for private medical services, with recommendations for companies like Huashan Medical and Aier Eye Hospital [11]. Blood Products - The report anticipates a favorable long-term growth path for the blood products industry, with companies like TianTan Biological and Boya Biological expected to benefit from increased demand and supply elasticity [11].